It was a good day for for the market and it was a great day for us. The Dow surged 380 points, or 5.8%, and closed at 6,926. If there were another hour of trading today the Dow probably would have hit 7,000. The Nasdaq soared 90 points, or 7%,Read more
Market Rebounds, Call Options Up
Start Half Positions In IBM
Weekly Wrap for 2/22/09
1. Commentary 2. Gold and Platinum 3. Trading Bank of America 4. 2008/ 2009 Portfolios 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary If 666 is the number of the beast, it must be that of a bear because it roared its ugly head at the market.Read more
Weekly Wrap for 2/16/09
1. Commentary 2. Oil and Gold 3. Options Education 4. Credit Spreads 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market was under tremendous pressure last week and as the saying goes, pressure bursts pipes. Wall Street took a back seat to Washington as the stimulusRead more
Trade Updates: Google Stop Hit/ Akamai Technologies Pops Higher
Weekly Wrap for 2/8/09
1. Commentary 2. Straddle’s Part 2 (Amazon Keeps on Rolling) 3. Financial Sector (open positions) 4. Akamai Technologies 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market had an outstanding week and it has been a minute since I have said that. For all of theRead more
Wednesday Morning Update
Biotech Grumblings
Genentech (DNA, $82.10, up $0.86) came out with some great news yesterday after the bell and said a late-stage study combining Avastin with Tarceva to treat lung cancer was a huge success. Tarceva is a drug from OSI Pharmaceutical’s (OSIP, $36.39, up $0.79) pipeline and is marketed by Genentech. TheRead more
Roche Goes Hostile
Roche threw us a curveball this morning and took its bid for Genentech (DNA, $80.95, down $3.14) directly to the shareholders. The company is now offering about $42 billion, or $86.50 a share for Genentech which is $2.50 less than the offer it made last July. Hogwash. Roche’s attempt toRead more
Weekly Wrap 1/25/09
1. Commentary 2. Financials 3. Techs 4. Biotechs 5. Earnings 6. Closing Thoughts ************************************************** 1. Commentary The market continued its slide as the all three major indexes lost ground again last week. There was strength in certain sectors while other sectors continued their volatile ways, especially the financial stocks. TheRead more